Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium. Show more

Location: Generaal De Wittelaan L11 A3, Mechelen, 2800, Belgium | Website: https://www.glpg.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

2.011B

52 Wk Range

$22.36 - $31.23

Previous Close

$30.49

Open

$30.49

Volume

124,742

Day Range

$30.22 - $30.58

Enterprise Value

-1.444B

Cash

3.297B

Avg Qtr Burn

-59.05M

Insider Ownership

0.00%

Institutional Own.

22.24%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

GLPG3667 Details
Dermatomyositis

Phase 3

Data readout

Filgotinib Details
Axial spondyloarthritis

Phase 3

Data readout

Filgotinib Details
Crohns disease

Phase 3

Update

GLPG3667 Details
Systemic lupus erythematosus

Phase 2

Data readout

GLPG5301 BCMA CAR-T Details
Multiple myeloma, High Refractory Multiple Myeloma

Phase 1/2

Data readout

GLPG5201 (CD19 CAR-T) Details
Small lymphocytic lymphoma , Chronic lymphocytic leukemia

Phase 1/2

Update

GLPG5101 (CD19 CAR-T) Details
Relapsed refractory non-Hodgkin’s Lymphoma (R/R NHL)

Phase 1/2

Update

GLPG1205 (GPR84 inhibitor) Details
Idiopathic pulmonary fibrosis

Failed

Discontinued

GLPG2737 (CFTR inhibitor) Details
Autosomal Dominant Polycystic Kidney Disease

Failed

Discontinued

GLPG3970 (SIK2/3 inhibitor) Details
Psoriasis, Rheumatoid arthritis, Ulcerative colitis, Systemic lupus erythematosus

Failed

Discontinued

GLPG5101 (CD19 CAR-T) Details
Systemic lupus erythematosus, Autoimmune disease

Failed

Discontinued

Ziritaxestat (GLPG1690) Details
Idiopathic pulmonary fibrosis

Failed

Discontinued

GLPG4716 (CHIT1/AMCase inhibitor) Details
Idiopathic pulmonary fibrosis

Failed

Discontinued